Skip to main content

Novo Nordisk

Novo Nordisk Finance Netherlands BV operates as a specialized financing subsidiary and debt issuing vehicle for Novo Nordisk A/S, the Danish global healthcare company. The operating parent discovers, develops, manufactures, and markets biological medicines for diabetes care, obesity management, hemophilia, and rare endocrine disorders under brands including Ozempic, Wegovy, and Victoza. Principal revenues and cash flows of the issuing vehicle derive from intercompany loan servicing, internal financing fees, and debt issuances guaranteed by Novo Nordisk A/S. Core end markets encompass healthcare systems, specialty pharmacies, hospital networks, and prescription patients globally through the parent company's commercial footprint. Positioned as a dedicated international financing vehicle, it supports capital structure management and global manufacturing facility expansion for Novo Nordisk. The company is incorporated and headquartered in Amsterdam, Netherlands, operating as a private subsidiary.

207 of the funds FundTelligence covers report a position in Novo Nordisk.

Legal name
NOVO NORDISK A/S
Sector
Health Care
Country
Denmark
Funds holding it
207
Exposure themes
Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health

Funds holding Novo Nordisk

Showing the 8 largest of 207 funds holding it.

Loading...